Evolution of hepatitis B virus polymerase and surface genes in patients receiving finite antiviral therapy
In conclusion, HBV genome continues to evolve during the courses of finite antiviral therapies. Pre-existing surface truncation mutations can be overtaken by the wild types after relapses. The sG44E/sE164G mutations are associated with failure of HBeAg seroclearance.
Authors
- Chih‐Yung Chiou
- Kung‐Hao Liang (ORCID: https://orcid.org/0000-0002-7593-5965)
- Ming‐Wei Lai (ORCID: https://orcid.org/0000-0002-3570-8565)
- Yu‐De Chu (ORCID: https://orcid.org/0000-0002-5496-8573)
- Chih‐Lang Lin (ORCID: https://orcid.org/0000-0002-1225-3895)
- Chao‐Wei Hsu
- Chau‐Ting Yeh
- P. P. K. Ho (ORCID: https://orcid.org/0000-0002-9770-0884)
Institutions
- Taipei Veterans General Hospital (TW)
- Chang Gung Memorial Hospital (TW)
- Keelung Chang Gung Memorial Hospital (TW)
- Linkou Chang Gung Memorial Hospital (TW)
Publication Details
- Journal
- Journal of Gastroenterology and Hepatology
- Published
- 2024-11-05
- DOI
- https://doi.org/10.1111/jgh.16791
- Citations
- 1
- Primary Topic
- Hepatitis B Virus Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.39